Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Nautilus Biotechnology, Inc.

Get SEC filing alerts via email and in your feed for Nautilus Biotechnology, Inc.

NAUT

Nautilus Biotechnology, Inc.

About Nautilus Biotechnology, Inc.

Nautilus Biotechnology develops a platform for comprehensive proteome analysis, enabling highly sensitive, scalable, and reproducible measurement of nearly all proteins and proteoforms in a sample. Combining advanced optics, fluidics, affinity reagents, and machine learning, it aims to revolutionize proteomics research, drug discovery, and diagnostics by providing deep biological insights and unlocking the full potential of the human proteome.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Nautilus Biotechnology, Inc.

1
1
Nautilus Biotechnology, Inc. Nautilus Biotechnology Reports $14.7 Million Net Loss in Q1 2026, Seeks Additional Funding

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Nautilus Biotechnology, Inc. Nautilus Biotechnology Reports $59M Net Loss for Fiscal Year 2025, Plans Phased Commercialization of Proteomics Platform

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Nautilus Biotechnology, Inc. Nautilus Biotechnology Reports Q3 2025 Financial Results with Improved Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Nautilus Biotechnology, Inc. Nautilus Biotechnology Reports $15M Net Loss in Q2 2025, Down from $18M in Q2 2024

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Nautilus Biotechnology, Inc. Nautilus Biotechnology Reports $16.6 Million Net Loss in Q1 2025, Focuses on Proteomics Development

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Nautilus Biotechnology, Inc. Nautilus Biotechnology Reports $70.8 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Nautilus Biotechnology, Inc. Navigate Biotechnology Reports Decline in Cash and Cash Equivalents, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments